Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can muscle wasting predict who suffers worst from chemo?

NCT ID NCT06274268

Knowledge-focused Sponsor: Centre Hospitalier Metropole Savoie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 08, 2026 · Last updated Oct 09, 2026 · Updated 1 time

Summary

Researchers are tracking 700 adults with solid tumors who are starting systemic anti-cancer treatment. The study measures body composition with bioimpedance and muscle performance with grip strength and chair-rise tests, plus activity trackers, to see whether sarcopenia predicts severe treatment-related toxicity during the first cycle. The goal is to learn if muscle status can serve as an early warning sign for who might need closer monitoring or dose adjustments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sarcopenia diagnostic tests including bioimpedance, grip strength, chair-rise, and activity trackers
What this could lead to
If sarcopenia predicts who gets hit hardest by chemotherapy side effects, doctors could one day use simple muscle tests to adjust doses before treatment starts.
What could go wrong
This is an observational study, so it can only show a link, not prove cause and effect. Sarcopenia may turn out to be a weak predictor once other factors like age and cancer type are accounted for.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oncology are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced toxicity neoplasm Sarcopenia Sedentary Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oncology Physical inactivity Sarcopenia Toxicity due to chemotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Metropole Savoie

    RECRUITING

    Chambéry, 73000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.